Climb Bio, Inc. filed a current report on August 14, 2026, disclosing that its collaborator Beijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient in a Phase 2 clinical trial in China for immunoglobulin A nephropathy on August 13, 2026.

Key Highlights

  • First Patient Dosed: Beijing Mabworks Biotech Co., Ltd. dosed the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China.
  • Event Date: The dosing announcement was made on August 13, 2026.
  • Collaboration: The trial is being conducted in collaboration with Climb Bio, Inc.
  • Trial Location: The Phase 2 clinical trial is being conducted in China.
  • Emerging Growth Company: Climb Bio, Inc. is designated as an emerging growth company under applicable securities regulations.

Beijing Mabworks Initiates Phase 2 IgA Nephropathy Trial in Collaboration with Climb Bio

According to the filing, on August 13, 2026, Beijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial being conducted in China. The trial is described in the filing as being conducted in collaboration with Climb Bio, Inc. (NASDAQ:CLYM), a Delaware-incorporated biopharmaceutical company headquartered at 20 William Street, Suite 145, Wellesley Hills, Massachusetts 02481.

The disclosure was made under Item 8.01 (Other Events) of the current report, which was filed with the SEC on August 14, 2026. The report was signed by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio, Inc. No additional clinical details, trial endpoints, timelines, or financial terms were disclosed in the filing.

Climb Bio, Inc. indicated in the filing that it is an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, and that it has not elected to use the extended transition period for complying with new or revised financial accounting standards.

What Was Disclosed

The filing reported that collaborator Beijing Mabworks Biotech Co., Ltd. dosed the first patient in a China-based Phase 2 clinical trial for immunoglobulin A nephropathy on August 13, 2026, in collaboration with Climb Bio, Inc.